Renoprotective role of the vitamin D receptor in diabetic nephropathy

Kidney International

Volumn 73, Issue 2, 2008, Pages 163-171

  Zhang, Z ^a   Sun, L ^a   Wang, Y ^a   Ning, G ^b   Minto, A W ^a   Kong, J ^a   Quigg, R J ^a   Li, Y C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Albuminuria; Diabetic nephropathy; Glomerulosclerosis; Reninangiotensin system; Vitamin D; Vitamin D receptor

Indexed keywords

ANGIOTENSINOGEN; CALCITRIOL; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GLUCOSE; NEPHRIN; RENIN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D RECEPTOR;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVATION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HYPERGLYCEMIA; JUXTAGLOMERULAR CELL; KIDNEY INJURY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION;

EID: 37549046405     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002572     Document Type: Article

References (57)

1. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
2. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
3. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281.
4. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-beta as the major mediator. J Am Soc Nephrol 2004; 15(Suppl 1): S55-S57.
5. Banba N, Nakamura T, Matsumura M et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684-690.
6. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
8. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
10. Andersen S, Tarnow L, Rossing P et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.
11. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391.
12. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39: 129-134.
13. Navar LG, Inscho EW, Majid SA et al. Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76: 425-536.
14. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
15. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 2003; 144: 2179-2183.
16. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
17. Zimpelmann J, Kumar D, Levine DZ et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000; 58: 2320-2330.
18. Singh R, Singh AK, Alavi N et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-880.
19. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039-F1045.
20. Gilbert RE, Krum H, Wilkinson-Berka J et al. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003; 20: 607-621.
21. Kelly DJ, Wilkinson-Berka JL, Allen TJ et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998; 54: 343-352.
22. Li YC, Qiao G, Uskokovic M et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90: 387-392.
23. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
24. Kong J, Li YC. Effect of angiotensin II type I receptor antagonist and angiotensin-converting enzyme inhibitor on vitamin d receptor null mice. Am J Physiol Regul Integr Comp Physiol 2003; 285: R255-R261.
25. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
26. Qiao G, Kong J, Uskokovic M et al. Analogs of 1alpha,25- dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96: 59-66.
27. Kestila M, Lenkkeri U, Mannikko M et al. Positionally cloned gene for a novel glomerular protein-nephrin - is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1: 575-582.
28. Gupta S, Clarkson MR, Duggan J et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000; 58: 1389-1399.
29. van Dijk C, Berl T. Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 2004; 5: 237-248.
30. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68: 1973-1981.
31. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
32. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
33. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
34. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
35. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
36. Abe H, Iehara N, Utsunomiya K et al. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factorbeta type II receptor-mediated manner. J Biol Chem 1999; 274: 20874-20878.
37. Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001; 158: 1733-1741.
38. Wang Y, Zhou J, Minto AW et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006; 70: 882-891.
39. Goldschmeding R, Aten J, Ito Y et al. Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 2000; 15: 296-299.
40. Aschenbrenner JK, Sollinger HW, Becker BN et al. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171-175.
41. Yanagisawa J, Yanagi Y, Masuhiro Y et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317-1321.
42. Zhang Z, Yuan W, Sun L et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced MCP-1 expression in mesangial cells by targeting NF-kappaB. Kidney Int 2007; 72: 193-201.
43. Kagami S, Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
44. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
45. Liebau MC, Lang D, Bohm J et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 290: F710-F719.
46. Yoo T-H, Li J-J, Kim J-J et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-1027.
47. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
48. Kaneshiro Y, Ichihara A, Takemitsu T et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70: 641-646.
49. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-1961.
50. Kaneshiro Y, Ichihara A, Sakoda M et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (Pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795.
51. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 2002; 62: 367-374.
52. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94: 9831-9835.
53. Taneda S, Pippin JW, Sage EH et al. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003; 14: 968-980.
54. Das AK, Pickett TM, Tungekar MF. Glomerular basement membrane thickness - a comparison of two methods of measurement in patients with unexplained haematuria. Nephrol Dial Transplant 1996; 11: 1256-1260.
55. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
56. Li YC, Bolt MJG, Cao L-P et al. Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. Am J Physiol Endocrinol Metab 2001; 281: E558-E564.
57. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984; 81: 1991-1995.